Publications by authors named "Sally Paredes"
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma, predominantly afflicting older adults. There remains a notable absence of data regarding DLBCL in older adults in Latin America.
Materials And Methods: We conducted a retrospective analysis of 608 newly diagnosed Latin American patients with DLBCL aged ≥65 years.
Article Synopsis
- * Among 118 patients treated between 2010 and 2019, those with RDW-CV values over 14% showed significantly lower overall survival rates (34% vs. 45%) and higher lymphoma-specific mortality (54% vs. 34%) over 4 years.
- * The study suggests that high RDW-CV is a potential and easy-to-use prognostic marker for evaluating risk in PTCL patients, indicating a need for further validation in future research. *
Purpose: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive disease caused by the human T-cell leukemia virus type 1. Real-world data of ATLL in Latin America are lacking.
Patients And Methods: We analyzed patients with ATLL (acute, lymphomatous, chronic, and smoldering) encountered in 11 Latin American countries between 1995 and 2019.
Introduction: We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemoimmunotherapy.
Patients And Methods: The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff ≥ 4 was determined using receiver operating characteristic analysis.
Article Synopsis
- Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), is a type of aggressive lymphoma linked to chronic EBV infection and has a poor response to standard chemotherapy.
- Diagnosis involves a thorough pathological assessment, primarily by detecting EBV-encoded RNA (EBER), but no definitive positive threshold exists, making it distinct from other lymphoma types.
- Risk stratification methods like the International Prognostic Index (IPI) and the Oyama score are used, and while management parallels that of EBV-negative DLBCL, EBV+ cases may have worse outcomes and could benefit from targeted therapies.
Article Synopsis
- The study investigates the significance of red blood cell distribution width (RDW) as a predictor of treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL).
- Among 121 DLBCL patients treated with standard chemoimmunotherapy, those with high RDW (> 14.6%) had a lower rate of complete response (CR) and a shorter overall survival (OS) compared to those with normal RDW (11.6%-14.6%).
- High RDW was found to be an independent adverse factor for both CR and OS, indicating its potential as a useful prognostic marker in DLBCL treatment outcomes.
Article Synopsis
- The study evaluated the neutrophil:lymphocyte ratio (NLR) in 121 Peruvian patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP treatment to determine its predictive and prognostic value.
- Patients with an NLR of 6 or higher had significantly poorer outcomes, including lower complete response rates and reduced 5-year progression-free survival (PFS) and overall survival (OS) rates.
- The findings suggest that NLR can provide additional prognostic information alongside existing indices, making it a valuable tool for assessing patient outcomes in DLBCL.